Members of PEPFAR's Scientific Advisory Board and Expert Working Groups met in October 2015 to discuss the most efficient and effective ways to prevent and treat HIV.
October 2015 Board Meeting
In accordance with the Federal Advisory Committee Act (FACA), the PEPFAR Scientific Advisory Board (SAB) serves the Global AIDS Coordinator in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS.
These issues are of concern as they influence the priorities and direction of PEPFAR’s evaluation and research, the content of national and international strategies and implementation, and the role of PEPFAR in the international discourse regarding appropriate and resourced responses.
The Board is composed of members appointed by the Coordinator. Membership is representative of the HIV/AIDS community, academia, international experts, partner government representatives, multilateral and bilateral agency representatives, foundations, advocates, and non-governmental organizations. Find out more about the Board members by reading their biographies.
NOTE: The recommendations provided by the Board do not necessarily represent the opinions of the U.S. government. These recommendations are submitted by the Scientific Advisory Board in its capacity as a federal advisory committee and meet the standards and regulations of the Federal Advisory Committee Act.
For additional information about the Scientific Advisory Board and the documentation of its compliance with the Federal Advisory Committee Act, please visit the FACA Database.
On March 6, 2015, the PEPFAR Scientific Advisory Board’s charter was renewed.
In order to maximize the productivity of the Board, the charter provides that the Coordinator may establish subcommittees or working groups to carry out assigned responsibilities. PEPFAR Expert Working Groups (EWGs) are established under that authority. For more information on PEPFAR Scientific Advisory Board EWGs, please see the EWG Terms of Reference.
There are currently two active EWGs:
The Test and START EWG was initiated after the exciting findings of the Strategic Timing of ART (START) trial were announced at the 2015 International AIDS Society Conference. The START trial established that immediate ART benefits all HIV-infected individuals considerably by lowering the risk of developing AIDS, tuberculosis, and other serious illnesses as well as the risk of death.
Together with data from previous studies showing that ART dramatically reduces the risk of HIV transmission, there is now strong scientific evidence that immediate HIV treatment with ART improves the health of HIV-infected individuals and lowers their viral load, thereby reducing the risk they will transmit HIV to others.
| U.S. Government interagency website managed by the Office of U.S. Global AIDS Coordinator|
and the Bureau of Public Affairs, U.S. State Department.
External Link Policy | Copyright Information | Privacy | FOIA